Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Psyence Biomedical (NASDAQ:PBM) Invests Up to $5 Million in PsyLabs to Advance US Ibogaine Program

Psyence Biomedical Ltd. (NASDAQ:PBM), a biopharmaceutical company developing nature-derived neuroplastogen therapeutics, has announced a cashInvestmentof up to 5 million dollars in Psyence Labs Ltd., alongside a value-matched share exchange between the two companies. The transactions, announced on September 23, 2026, are intended to support …

Nitish Kishor | 23 September 2026

Johnson & Johnson (NYSE:JNJ) Data Shows TECVAYLI Combination May Approach Normal Life Expectancy in Multiple Myeloma

Johnson & Johnson (NYSE:JNJ) has announced new model-based analysis from its Phase 3 MajesTEC-3 study, evaluating TECVAYLI plus DARZALEX FASPRO in patients with relapsed or refractory multiple myeloma who had received one to three prior lines of therapy. Using a relative survival mixture cure …

Nitish Kishor | 23 September 2026

Artelo Biosciences (NASDAQ:ARTL) Files Patent for ART27.13 in Obesity Following Unexpected Mouse Study Results

Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on lipid-signaling pathways, has filed a provisional patent application covering the use of ART27.13 for obesity treatment. The filing covers the compound both as a standalone therapy and in combination with GLP-1 receptor agonists such …

Nitish Kishor | 23 September 2026

Armata Pharmaceuticals (NYSE American:ARMP) Receives $3.7 Million in Additional Defense Department Funding for Phase 3 Bacteriophage Program

Armata Pharmaceuticals, Inc. (NYSE American:ARMP), a late clinical-stage biotechnology company focused on bacteriophage therapeutics, has received an additional 3.7 million dollars in non-dilutive funding from the U.S. Department of War to support Phase 3 development activities for its lead candidate, AP-SA02. The funding was …

Nitish Kishor | 23 September 2026

Roivant (NASDAQ:ROIV) Discontinues IMVT-1402 Development in Cutaneous Lupus After Missed Primary Endpoint

Roivant (NASDAQ:ROIV) announced topline results from Period 1 of a proof-of-concept trial evaluating IMVT-1402, known as imeroprubart, for the treatment of cutaneous lupus erythematosus, conducted by its majority-ownedSubsidiaryImmunovant. The randomized, double-blind, placebo-controlled study enrolled 57 patients and assessed percent change from baseline in the …

Nitish Kishor | 23 September 2026

NewtekOne, Inc. (NASDAQ:NEWT) Dividend Yields 6.51% as Net Income Rises to $14.6 Million Despite Lower EPS

NewtekOne declared a quarterlyCash Dividendof $0.19 per share on its common stock on September 14, 2026, payable October 1 to shareholders of record September 24. The current quarterly rate equals $0.76 annualized. The board separately declared a dividend on its 8.500% Fixed-Rate Reset Non-Cumulative …

Nitish Kishor | 23 September 2026

New Jersey Resources Corporation (NYSE:NJR) Dividend Rises to $0.50 for 31st Consecutive Annual Increase

New Jersey Resources' board unanimously approved an increase in the quarterly dividend rate to $0.50 per share from $0.475, effective with the dividend payable October 1, 2026 to shareowners of record September 24. The new annual dividend rate is $2.00 per share. The company …

Nitish Kishor | 23 September 2026

Invitation Homes Inc. (NYSE:INVH) Dividend Yields 4.42% as AFFO Per Share Grows 5.9% to $0.44

Invitation Homes declared a quarterlyCash Dividendof $0.30 per share, payable on or before October 16, 2026 to shareholders of record September 24. The current quarterly rate equals $1.20 annualized.

Nitish Kishor | 23 September 2026

Getty Realty Corporation (NYSE:GTY) Dividend Yields 6.59% as AFFO Guidance Raised to $2.52-$2.54 Per Share

Getty Realty's board declared aCash Dividendof $0.485 per common share on July 21, 2026, payable October 8 to holders of record September 24. The current quarterly rate equals $1.94 annualized. Getty reportedOperating Cash Flowof approximately $93.947 million and cash dividends of approximately $80.739 million …

Nitish Kishor | 23 September 2026

Designer Brands Inc. (NYSE:DBI) Dividend Yields 3.13% as Adjusted EPS Beats Estimates by 750%

Designer Brands declared a quarterlyCash Dividendof $0.05 per share on both Class A and Class B common shares on September 9, 2026, payable October 7 to shareholders of record September 24. The rate is unchanged from the prior quarter's dividend, paid July 8, 2026. …

Nitish Kishor | 23 September 2026
Support

Hi! How can we help you today?

Loading…